ArticleFrontiers in pharmacology2026
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: The anti-obesity effects of GGT were evaluated using a tiered experimental approach comprising C2C12 myotubes, high-fat diet (HFD)-induced obese C57BL/6J mice, and Results: GGT enhanced glucose uptake and increased the expression of insulin-responsive and mitochondrial regulatory genes in C2C12 myotubes. In HFD-fed mice, GGT attenuated body weight gain, improved glucose tolerance and insulin sensitivity, and alleviated hepatic steatosis and adipose hypertrophy, accompanied by suppression of lipogenic genes and induction of β-oxidation markers. In Conclusion: GGT improves obesity-related metabolic dysfunction by coordinately regulating glucose homeostasis, lipid metabolism, and energy expenditure across cellular, nematode, and murine models. These findings provide preclinical evidence supporting GGT as a multi-targeted herbal intervention for obesity and metabolic disorders and warrant further targeted mechanistic studies and clinical investigations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.